stock.name

Vertex Pharmaceuticals, Inc.

VRTX

Market Cap$123.62B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Vertex Pharmaceuticals, Inc.Vertex Pharmaceuticals, Inc.30.80%22%12.1-

Earnings Call Q4 2023

February 5, 2024 - AI Summary

Vertex Pharmaceuticals reported strong financial results for the fourth quarter and full year 2023, with revenue growth of 9% YoY in Q4 and 11% YoY for the full year.
The company achieved full-year CF product revenues of $9.87 billion, representing 11% growth versus 2022.
Vertex received approvals for CASGEVY, its CRISPR/Cas9-based therapy, in sickle cell disease and beta-thalassemia in multiple countries, and the launch is off to a strong start.

Exclusive for Stockcircle Pro members

Sign upSign Up
$450.17

Target Price by Analysts

4.5% downsideVertex Pharmaceuticals Target Price DetailsTarget Price
$656.28

Current Fair Value

39.2% upside

Undervalued by 39.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$123.62 Billion
Enterprise Value$113.81 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$15.42
Beta0.0
Outstanding Shares258,053,387
Avg 30 Day Volume1,225,052

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio30.75
PEG53.83
Price to Sales12.09
Price to Book Ratio6.64
Enterprise Value to Revenue11.17
Enterprise Value to EBIT25.87
Enterprise Value to Net Income28
Total Debt to Enterprise0
Debt to Equity0.02

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Vertex Pharmaceuticals, Inc.

CEO: Jeffrey Leiden